- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03989492
Role of the Sympathetic Nervous System in Rosacea
October 31, 2023 updated by: Kristen Metzler-Wilson, Indiana University
Rosacea is a common skin disorder which causes facial redness and inflammation in about 16 million Americans, from an unknown cause.
Many triggers of rosacea symptoms are stressors that affect the sympathetic ("fight or flight") portion of the nervous system, and a recent pilot study suggests there is sympathetic dysfunction in rosacea.
This project will benefit patients, clinicians, and basic scientists by increasing our understanding of sympathetic nervous system involvement in rosacea symptoms in order to develop improved treatments for patients with rosacea.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
210
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kristen Metzler-Wilson, PT, PhD
- Phone Number: 317-278-1871
- Email: dptlab@iupui.edu
Study Contact Backup
- Name: Thad Wilson, PhD
- Email: thad.wilson@uky.edu
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University
-
Contact:
- Kristen Metzler-Wilson, PT, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Otherwise healthy males and non-pregnant/non-lactating females with mild to moderate erythematotelangiectactic rosacea, as well as age-sex matched healthy control subjects.
Exclusion Criteria:
- Neurological, cardiovascular, respiratory, metabolic, muscular, or other dermatological disorders
- Current history of alcohol and/or drug abuse
- Known allergies or hypersensitivities to medications/drugs that are used in the protocol
- Current smoking or regular smoking within the last 2 years
- Body mass index > 35 kg/m2
- Medications or supplements which are known to affect neural, cardiovascular, or muscular responses
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autonomic responses to stressors
Protocol 1: mental math and handgrip exercise.
Protocol 2: systemic stressors and end-organ receptor stimulation.
Protocol 3: local heating.
|
Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise.
Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation.
Protocol 3: skin end organ responses will be measured at baseline and during local heating.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin blood flow
Time Frame: Immediate (during the single-day study). This study consists of a one-day protocol, during which this outcome is measured.
|
laser Doppler flowmetry
|
Immediate (during the single-day study). This study consists of a one-day protocol, during which this outcome is measured.
|
Skin sympathetic nerve activity
Time Frame: Immediate (during the single-day study). This study consists of a one-day protocol, during which this outcome is measured.
|
microneurography
|
Immediate (during the single-day study). This study consists of a one-day protocol, during which this outcome is measured.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kristen Metzler-Wilson, PT, PhD, Indiana University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 24, 2019
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
June 12, 2019
First Submitted That Met QC Criteria
June 14, 2019
First Posted (Actual)
June 18, 2019
Study Record Updates
Last Update Posted (Actual)
November 2, 2023
Last Update Submitted That Met QC Criteria
October 31, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R15AR069912-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rosacea
-
Amorepacific CorporationCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaKorea, Republic of
-
Actavis Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States
-
University of California, DavisCompletedRosacea | Ocular Rosacea | Cutaneous RosaceaUnited States
-
bioRASI, LLCCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Bionou Research, S.L.RecruitingRosacea | Rosacea, Papulopustular | Rosacea Papular TypeSpain
-
Galderma R&DCompleted
-
Cutera Inc.CompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Eye Associates of Central TexasWithdrawn
-
Dermata TherapeuticsActive, not recruiting
-
AiViva BioPharma, Inc.Withdrawn
Clinical Trials on systemic and local stressors
-
M.D. Anderson Cancer CenterNot yet recruitingOligoProgressive Metastatic DiseaseUnited States
-
The Forsyth InstituteBoston University; Göteborg UniversityCompleted
-
Istituto Ortopedico RizzoliCompleted
-
Australasian Gastro-Intestinal Trials GroupCancer Council Victoria; Walter and Eliza Hall Institute of Medical ResearchRecruitingColorectal Cancer | Oligometastatic DiseaseAustralia
-
Hospital Italiano de Buenos AiresRecruitingCarpal Tunnel SyndromeArgentina
-
M.D. Anderson Cancer CenterActive, not recruiting
-
Amsterdam UMC, location VUmcRecruitingRecurrence | Colorectal Cancer | Surgery | Chemotherapy Effect | Liver Metastases | Liver Metastasis Colon CancerNetherlands
-
Oregon Health and Science UniversityRecruiting
-
Vastra Gotaland RegionNot yet recruitingNon Small Cell Lung CancerSweden